Lercanidipine decreases vascular matrix metalloproteinase-2 activity and protects against vascular dysfunction in...

Area of Science:

• Cardiovascular Pharmacology
• Diabetic Complications
• Oxidative Stress Research

Background:

• Abnormal matrix metalloproteinases (MMPs) activity contributes to cardiovascular diseases.
• Hyperglycemia exacerbates MMPs activity via increased oxidative stress.
• Lercanidipine's antioxidant properties were investigated for their potential to mitigate MMPs in diabetes.

Purpose of the Study:

• To evaluate if lercanidipine's antioxidant effects could reduce matrix metalloproteinases-2 (MMP-2) expression and activity in diabetic rats.
• To assess lercanidipine's impact on vascular reactivity, oxidative stress, and MMP-2/tissue inhibitor of metalloproteinases-2 (TIMP-2) balance in a diabetic model.

Main Methods:

• Diabetes was induced in rats using alloxan. Treated groups received lercanidipine (2.5 mg/kg/day) or tap water for six weeks.
• Vascular reactivity, blood pressure, aortic MMP-2 levels (zymography), and MMP-2/TIMP-2 mRNA expression (RT-PCR) were assessed.
• Plasma thiobarbituric acid reactive substances (TBARS) were measured to quantify oxidative stress.

Main Results:

• Lercanidipine demonstrated antihypertensive effects and improved endothelium-dependent vasorelaxation in diabetic rats.
• Diabetic rats showed increased aortic MMP-2 levels and oxidative stress, which were attenuated by lercanidipine.
• A significant 16-fold increase in the MMP-2/TIMP-2 mRNA ratio in diabetic aortas was completely reversed by lercanidipine treatment.

Conclusions:

• Lercanidipine's antioxidant actions in diabetic rats are linked to reduced oxidative stress and normalization of MMP-2 levels.
• The drug effectively reversed the imbalance in vascular MMP-2/TIMP-2 expression, suggesting a protective role against diabetic cardiovascular complications.
• Lercanidipine offers potential therapeutic benefits for managing cardiovascular risks associated with diabetes.